Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

154 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders.
Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H, Marignier R, Collongues N; NOMADMUS group, under the aegis of OFSEP, SFSEP. Ciron J, et al. Among authors: brassat d. Rev Neurol (Paris). 2018 Apr;174(4):255-264. doi: 10.1016/j.neurol.2017.11.005. Epub 2018 Mar 30. Rev Neurol (Paris). 2018. PMID: 29606320 Review. English.
Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability.
Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R, Brassat D. Zéphir H, et al. Among authors: brassat d. J Neurol. 2015 Oct;262(10):2329-35. doi: 10.1007/s00415-015-7852-y. Epub 2015 Jul 21. J Neurol. 2015. PMID: 26194198
Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, Bourre B, Brochet B, Camdessanche JP, Labauge P, Moreau T, Brassat D, Stankoff B, de Seze J, Vukusic S, Marignier R; NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP). Montcuquet A, et al. Among authors: brassat d. Mult Scler. 2017 Sep;23(10):1377-1384. doi: 10.1177/1352458516678474. Epub 2016 Nov 25. Mult Scler. 2017. PMID: 27885065
Neuromyelitis optica in France: a multicenter study of 125 patients.
Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C, Tchikviladzé M, Outteryck O, Vukusic S, Fleury M, Fontaine B, Brassat D, Clanet M, Milh M, Pelletier J, Audoin B, Ruet A, Lebrun-Frenay C, Thouvenot E, Camu W, Debouverie M, Créange A, Moreau T, Labauge P, Castelnovo G, Edan G, Le Page E, Defer G, Barroso B, Heinzlef O, Gout O, Rodriguez D, Wiertlewski S, Laplaud D, Borgel F, Tourniaire P, Grimaud J, Brochet B, Vermersch P, Confavreux C, de Seze J. Collongues N, et al. Among authors: brassat d. Neurology. 2010 Mar 2;74(9):736-42. doi: 10.1212/WNL.0b013e3181d31e35. Neurology. 2010. PMID: 20194912
Neuromyelitis optica and pregnancy.
Bourre B, Marignier R, Zéphir H, Papeix C, Brassat D, Castelnovo G, Collongues N, Vukusic S, Labauge P, Outteryck O, Fontaine B, Vermersch P, Confavreux C, de Seze J; NOMADMUS Study Group. Bourre B, et al. Among authors: brassat d. Neurology. 2012 Mar 20;78(12):875-9. doi: 10.1212/WNL.0b013e31824c466f. Epub 2012 Mar 7. Neurology. 2012. PMID: 22402855
[Nosology and etiologies of acute longitudinally extensive transverse myelitis].
Collongues N, Papeix C, Zéphir H, Audoin B, Cotton F, Durand-Dubief F, Vukusic S, Brassat D, Laplaud D, Marignier R; Groupe Nomadmus. Collongues N, et al. Among authors: brassat d. Rev Neurol (Paris). 2014 Jan;170(1):6-12. doi: 10.1016/j.neurol.2013.04.008. Epub 2013 Nov 21. Rev Neurol (Paris). 2014. PMID: 24269116 French.
Efficacy of rituximab in refractory neuromyelitis optica.
Collongues N, Brassat D, Maillart E, Labauge P, Ouallet JC, Carra-Dalliere C, Moreau T, Bourre B, Papeix C, Brochet B, Audoin B, Vukusic S, de Seze J, Marignier R; OFSEP and CFSEP. Collongues N, et al. Among authors: brassat d. Mult Scler. 2016 Jun;22(7):955-9. doi: 10.1177/1352458515602337. Epub 2015 Sep 11. Mult Scler. 2016. PMID: 26362900
Efficacy of rituximab in refractory RRMS.
Durozard P, Maarouf A, Boutiere C, Ruet A, Brochet B, Vukusic S, Carra-Dalliere C, Labauge P, Mathey G, Debouverie M, Papeix C, Maillart E, Lubetzki C, Bensa C, Gout O, Giannesini C, Stankoff B, Ciron J, Brassat D, Pelletier J, Rico Lamy A, Audoin B. Durozard P, et al. Among authors: brassat d. Mult Scler. 2019 May;25(6):828-836. doi: 10.1177/1352458518772748. Epub 2018 May 3. Mult Scler. 2019. PMID: 29722639
154 results